|Bid||4,528.00 x 0|
|Ask||4,533.00 x 0|
|Day's Range||4,512.00 - 4,543.00|
|52 Week Range||3,401.00 - 4,822.00|
|Beta (3Y Monthly)||1.08|
|PE Ratio (TTM)||392.16|
|Earnings Date||Jan 30, 2020 - Feb 3, 2020|
|Forward Dividend & Yield||180.00 (3.99%)|
|1y Target Est||6,017.00|
Local rare disease drugmaker Sarepta Therapeutics Inc. is expanding its efforts in the gene therapy field, signing a deal this week with a North Carolina startup to develop up to eight new treatments.
− Growth in the near- and medium-term will also be driven by the expansion of Takeda’s current 14 global growth brands
Moody's Investors Service ("Moody's") has today affirmed Nidda BondCo GmbH's ("Nidda" or "the group") B3 corporate family rating and B3-PD probability of default rating (PDR). Concurrently, Moody's has affirmed the B2 ratings on the E735 million 1st lien senior secured notes, the existing E406 million and E235 million 1st lien term loan B, the E759 million and GBP 266 million term loan C, and the E400 million revolving credit facility, all issued by Nidda Healthcare Holding GmbH ("Nidda Healthcare"); and assigned a B2 rating to the add-on term loan E and the tap on the existing senior secured notes, which in total will be E760 million.
Data Presented at the 2019 American College of Allergy, Asthma and Immunology Annual Meeting
The CAR-T wave has died down among biotech investors, but Takeda Pharmaceuticals could help reinvigorate the space with its venture into CAR-NK. Continue reading...
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. NINLARO is currently not approved for this specific use.
Takeda Pharmaceutical Co's experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but it failed to protect against one type of the virus in people with no prior exposure to dengue. Takeda's vaccine was 80.2% effective at preventing dengue among children and teens in the year after they got the shot, according to results of a Phase III study published in the New England Journal of Medicine on Wednesday. Sanofi's Dengvaxia - the world's first dengue vaccine - had demonstrated 59.2% overall efficacy in the first year of follow-up based on combined results from two late-stage trials.
− New England Journal of Medicine publishes primary endpoint analysis from ongoing Phase 3 study of Takeda’s dengue vaccine candidate
– Company Leadership to Present 20 Abstracts in Oncology and Nine in Hematology Throughout Conference, Showcasing Takeda’s Unique Expertise in Blood Cancers and Bleeding Disorders
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other cancers. Under the agreement, Takeda will receive access to MD Anderson’s CAR NK platform and the exclusive rights to develop and commercialize up to four programs, including a CD19-targeted CAR NK-cell therapy and a B-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy. Takeda and MD Anderson will also conduct a research collaboration to further develop these CAR NK programs.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG (“STADA”), an international pharmaceutical company, for a total value of $660 million USD. The portfolio includes over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States, which form part of Takeda’s Growth & Emerging Markets Business Unit. This is Takeda’s fourth divestment transaction in the past six months that contributes to the Company’s goal to divest approximately $10 billion USD in non-core assets to focus on its five key business areas and commitment to accelerating its deleveraging following its acquisition of Shire.
OSAKA, Japan-- -- FY2019 H1 revenue 1660.2 billion yen, up +88.5% versus prior year mainly due to acquisition of Shire and solid performance of 14 global growth brands Strong core operating profit * of 541.6 billion yen, up +155.5% versus FY2018 H1 and Underlying Core Operating Profit Margin of 32.2% driven by synergies, OPEX, and improved product mix Raising full year profit guidance to reflect strong ...
New biopharma startup Cyclerion Therapeutics has stumbled out of the gate, disclosing Wednesday that one of its lead drug candidates failed in a mid-stage study.
Positive findings on clinical endpoints for Budesonide Oral Suspension (BOS) presented during ACG 2019 Presidential Plenary Session LEXINGTON, Mass. , Oct. 28, 2019 /PRNewswire/ -- Takeda Pharmaceuticals ...
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 21.) Aprea Therapeutics Inc (NASDAQ: APRE ) AVITA ...
− Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activatio
- Latest real-world data presented at UEG Week 2019 complements the extensive body of clinical evidence for the gut-selective biologic vedolizumab in biologic-naïve patients with m
Takeda Pharmaceutical Co. Ltd. is shedding dozens of products and an undisclosed number of employees in a $200 million deal. But the Japanese drugmaker is reviving plans to occupy Cambridge’s iconic Genzyme building.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 14.) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals ...
Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million. The sale, which Takeda said in a statement is expected to close in the quarter ending March, comes as Japan's biggest drugmaker looks to trim its debt following the $59 billion purchase of Shire.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa (NEMEA) countries within its Growth and Emerging Markets Business Unit to Acino for a total value in excess of $200 million USD. “The divestment of non-core assets sold in NEMEA represents the continued execution of our strategy to optimize our portfolio, invest in the defined core business areas, and accelerate our progress toward reaching our target leverage ratio,” said Costa Saroukos, Chief Financial Officer, Takeda.